Sub-threshold DRG Stimulation vs Sham in Established Responders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if sub-threshold dorsal root ganglion (DRG) stimulation provides pain relief beyond placebo in adults with chronic neuropathic pain who already have an implanted DRG stimulator. The main questions it aims to answer are:

* Does sub-threshold DRG stimulation reduce daily pain intensity compared with sham stimulation?
* How does sub-threshold stimulation affect sleep, mood, and daily activity?

Researchers will compare active sub-threshold DRG stimulation to sham (device switched off) to see if stimulation has a genuine effect on pain and wellbeing.

Participants will:

* Be randomly assigned to receive either active sub-threshold DRG stimulation or sham stimulation for 5 days, followed by the opposite condition for another 5 days.
* Complete short electronic diaries twice daily about their pain, sleep, mood, and activity.
* Attend study visits for safety checks and assessments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TransGrade Multimodal Neuromodulation of the Dorsal Root Ganglion Ensemble for Refractory Neuropathic Pain

NCT03318250

Neuropathic Pain Pain, Chronic

TERMINATED NA

Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy

NCT04909138

CRPS (Complex Regional Pain Syndromes) Radiculopathy Peripheral Neuropathy

RECRUITING NA

Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms

NCT04988321

Diabetic Neuropathy, Painful

COMPLETED NA

Effects of Repetitive Electric Sensory Stimulation (RSS) as Intervention in Complex-regional-pain-syndrome Type I (CRPS)

NCT01915329

Complex Regional Pain Syndrome Type I of the Upper Limb

UNKNOWN NA

Comparative Study in Patients With Refractory Chronic Lower Limb Neuropathic Pain and/or Back Neuropathic Pain.

NCT04852107

Pain, Neuropathic

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neuropathic pain is a chronic condition that affects 6-10% of adults and is often resistant to conventional drug therapy. The dorsal root ganglion (DRG) has emerged as an important therapeutic target, as abnormal firing in DRG neurons contributes to peripheral and central sensitization. DRG stimulation (DRGS) delivers mild electrical pulses through implanted leads placed near the DRG. Compared with traditional spinal cord stimulation, DRGS provides highly targeted pain relief with fewer unwanted sensations.

Over the past decade, DRGS has become an established treatment for conditions such as complex regional pain syndrome (CRPS), causalgia, chronic low back pain, and post-surgical neuropathic pain. Modern programming favors sub-threshold settings, in which stimulation is delivered below the level that causes tingling sensations (paresthesias). Although widely adopted, the specific contribution of sub-threshold stimulation has never been confirmed in a sham-controlled trial.

This study is the first randomized, double-blind, sham-controlled trial to directly evaluate whether sub-threshold DRG stimulation provides pain relief beyond placebo. Adults with an implanted DRG stimulator who have shown sustained pain relief will be randomized in a two-period crossover design to receive either active sub-threshold stimulation or sham stimulation, each for 5 days, with a washout period in between.

The primary objective is to determine whether sub-threshold DRG stimulation reduces mean daily pain intensity compared with sham. Secondary objectives include assessing sleep quality, mood, daily activity, and safety/tolerability. Exploratory measures include device logs and rescue medication use.

The findings of this trial will provide critical evidence on the efficacy of sub-threshold DRG stimulation, helping to inform clinical guidelines, payer decisions, and neuromodulation programming strategies worldwide.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathic Pain Complex Regional Pain Syndromes (CRPS) Causalgia Chronic Pain Low Back Pain Pelvic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomised, double blinded, sham study

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subtreshhold DRG-S

Active Sub-threshold DRG Stimulation Participants receive sub-threshold dorsal root ganglion (DRG) stimulation. Device amplitude is individually titrated to 80% of the perception threshold, ensuring no paresthesia is felt. Frequency and pulse width remain unchanged from each participant's established clinical settings. Stimulation is delivered continuously for 5 days.

Group Type ACTIVE_COMPARATOR

Subtreshhold DRG-S

Intervention Type DEVICE

Continuous electrical stimulation delivered through an implanted DRG neurostimulator. Amplitude is set individually to 80% of each participant's perception threshold, ensuring no paresthesia is produced. Frequency and pulse width remain unchanged from the participant's established therapeutic settings. This sub-threshold programming distinguishes the intervention from suprathreshold (paresthesia-based) DRG stimulation used in earlier studies.

Sham

Sham Stimulation Participants receive sham stimulation. The implanted DRG stimulator is switched off, with device interrogation logs masked to maintain blinding. The sham condition lasts for 5 days.

Group Type SHAM_COMPARATOR

Sham

Intervention Type OTHER

The implanted DRG stimulator remains switched off for the entire 5-day period. Device interrogation logs are masked to maintain blinding. No electrical stimulation is delivered, allowing a placebo-controlled comparison with active sub-threshold stimulation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Subtreshhold DRG-S

Continuous electrical stimulation delivered through an implanted DRG neurostimulator. Amplitude is set individually to 80% of each participant's perception threshold, ensuring no paresthesia is produced. Frequency and pulse width remain unchanged from the participant's established therapeutic settings. This sub-threshold programming distinguishes the intervention from suprathreshold (paresthesia-based) DRG stimulation used in earlier studies.

Intervention Type DEVICE

Sham

The implanted DRG stimulator remains switched off for the entire 5-day period. Device interrogation logs are masked to maintain blinding. No electrical stimulation is delivered, allowing a placebo-controlled comparison with active sub-threshold stimulation.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults, age 18 years or older
* Implanted with a dorsal root ganglion (DRG) stimulator for chronic neuropathic pain
* Have experienced at least 50% reduction in pain for 3 months or longer on standard DRG therapy
* Stable pain medication regimen for at least 4 weeks before enrollment
* Able and willing to complete electronic diaries and attend study visits

Exclusion Criteria

* Active infection or wound complication at the stimulator implant site
* Significant psychiatric illness (for example, uncontrolled depression or psychosis)
* Planned surgery, device reprogramming, or medication changes during the study period
* Currently pregnant or breastfeeding
* Occurrence of any adverse event that meets predefined withdrawal criteria during the study (such as intolerable pain or device-related complications)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No